Dupixent Receives First-in-World Approval for Adults with Uncontrolled COPD with Raised Blood Eosinophils

Scientists have reported exciting news coming out of Europe: dupilumab, a biologic treatment aimed at an underlying cause of chronic obstructive pulmonary disease (COPD), has been approved for use in adults with the condition. This marks a significant milestone in the field of respiratory medicine and will offer hope to the millions of people living with COPD worldwide. The drug has been tested in two Phase 3 trials showing it can significantly reduce the frequency of exacerbations and improve lung function and health-related quality of life. The European Commission (EC) approved the treatment based on these trials.

Additionally, Regeneron and Sanofi are developing another biologic treatment for COPD patients called itepekimab, which inhibits the interleukin-33 (IL-33) pathway. This treatment is currently in Phase 3 trials. COPD is a progressive disease that affects millions worldwide and can significantly impair individuals' ability to perform daily activities and negatively impact their overall quality of life. The approval of dupilumab marks a significant step forward in treating this condition. It is the first new treatment approach for COPD in more than a decade and offers improved efficacy and reduced side effects compared to existing treatments.

This approval by the EC applies to adults with COPD who are already on a combination of inhaled corticosteroids, long-acting beta-agonists, and long-acting muscarinic antagonists or a combination of long-acting beta-agonists and long-acting muscarinic antagonists if inhaled corticosteroids are not appropriate. Regeneron and Sanofi plan to make dupilumab available to COPD patients in countries outside the EU. The companies are currently working with regulatory authorities worldwide to bring the treatment to more countries as quickly as possible.

Regeneron's President and Chief Scientific Officer, George D. Yancopoulos, Ph.D., who is also a principal inventor of dupilumab, expressed enthusiasm for the new treatment, stating, "With this approval, we are proud that Dupixent has the potential to redefine the treatment landscape in yet another disease, as a first-in-class therapy demonstrating unprecedented improvements on exacerbations and lung function, as well as improving health-related quality of life across two large Phase 3 trials."

In conclusion, the approval of dupilumab for adults with uncontrolled COPD with raised blood eosinophils is a significant development in respiratory medicine. It is the first new treatment for COPD in over a decade and the first therapy to target an underlying cause of the disease. COPD patients worldwide will potentially benefit from this novel treatment approach. Additionally, research on the IL-33 pathway by Regeneron and Sanofi may provide even more treatment options for people with COPD in the near future.

Read more

Bidenomics is Working!! <img src="https://cdn.dimethyldev.com/general/emojis/1f633.png" width="32" height="32" align="absmiddle"> [&quot;We are proud of Bidenomics!&quot; - Kamala Harris]

Youtube Shorts: 😳 ["We are proud of Bidenomics!" - Kamala Harris] Posted on July 6, 2024 11:38:46 AM PDT by Republican Wildcat Topic: Business/Economy | Chit/Chat | Miscellaneous Keywords: bideneffect, bidenomics, economcy, economy, kamala, kamalaharris Navigation: use the links below to view more comments. First 1-20, 21